# Translating AMR Genomic Data Into Policy ## Quick Answer - Genomic surveillance data becomes policy-relevant when laboratories connect resistance genotypes to phenotypic susceptibility results and epidemiological context from official surveillance frameworks. - Policymakers should prioritize data visualization and plain-language risk summaries that translate laboratory findings into intervention options for clinical and public health teams. - A key limitation is that genomic data alone cannot establish treatment protocols or regulatory decisions without confirmatory culture-based testing and standardized interpretive criteria. ## The Policy Translation Problem in Genomic AMR Surveillance Whole-genome sequencing and other genomic methods generate large volumes of antimicrobial resistance data that can inform public health decisions. The gap between laboratory output and policy action remains wide. Public health officials often receive resistance gene profiles, sequence types, and phylogenetic clusters without a clear framework for interpreting what those findings mean for clinical practice, infection control, or stewardship programs. The translation problem has several distinct components. First, genomic data are probabilistic and context dependent. A resistance gene may be present in a bacterial genome but not expressed under clinical conditions. Second, the data formats used by bioinformatic pipelines differ from the interpretive frameworks used by clinical laboratories. Third, the communication pathways between genomic laboratories and policy bodies are often informal or absent. The World Health Organization identifies antimicrobial resistance as a global public health concern that requires coordinated surveillance and stewardship across human health, animal health, and environmental sectors. Genomic data can support these coordinated efforts when the data is interpreted within established surveillance frameworks. The practical outcome of translation is a policy document, an intervention recommendation, or a stewardship action that changes how antibiotics are used or how infections are managed. Without translation, genomic data remains an academic exercise with limited public health impact. The framework described in this article provides a structured approach for moving from raw genomic output to policy-relevant recommendations. ## Core Principles for Genomic Data Translation ### Data Quality and Authenticated Reference Materials The foundation of any policy translation is data quality. Genomic surveillance depends on accurate sequencing, reliable bioinformatics, and appropriate reference materials. Authenticated bacterial strains and culture collections provide the quality control necessary for validating sequencing runs and bioinformatic pipelines. The American Type Culture Collection maintains authenticated biological materials that serve as reference standards for laboratory quality assurance. Using authenticated reference strains allows laboratories to verify that their sequencing and analysis workflows produce consistent results across runs and over time. Quality control in genomic surveillance involves several layers. The sequencing facility must demonstrate that the instruments are calibrated and that the data output meets established quality metrics. The bioinformatic pipeline must be validated against known reference genomes. The interpretation of resistance genes must be checked against phenotypic susceptibility testing results. Each layer of quality control contributes to the confidence that policymakers can place in the final recommendations. ### Standards-Based Interpretation Genomic data does not exist in a vacuum. The interpretation of resistance genes and mutations requires connection to established standards for antimicrobial susceptibility testing. The Clinical and Laboratory Standards Institute provides standards-based approaches for antimicrobial susceptibility testing that serve as the foundation for clinical interpretation. Genomic predictions of resistance should be validated against phenotypic testing results using these standards. The connection between genotype and phenotype is not always straightforward, and the standards provide the interpretive framework for understanding what the genomic data means in clinical terms. The relationship between genomic data and phenotypic susceptibility testing is bidirectional. Genomic data can identify resistance mechanisms that may not be captured by routine phenotypic testing. Phenotypic testing can confirm whether the resistance genes are expressed and whether they affect the minimum inhibitory concentration of the antibiotic. The policy translation process must acknowledge that genomic data is a screening tool that requires phenotypic confirmation for clinical decisions. ## The Translation Framework ### Step 1: Define the Policy Question The first step in translating genomic data to policy is to define the specific policy question that the data will address. The question may be about the emergence of a new resistance mechanism, the spread of a resistant clone in a healthcare facility, or the effectiveness of a stewardship intervention. The policy question determines the type of genomic data needed, the analysis methods required, and the format of the final recommendation. A well-defined policy question includes the population of interest, the time frame, the geographic scope, and the decision that the policy will inform. For example, a policy question about the spread of carbapenem-resistant Enterobacterales in a hospital network requires different data than a question about the prevalence of a specific resistance gene in a national surveillance program. The policy question also determines the level of evidence needed. A question about a localized outbreak may require rapid genomic analysis with limited data, while a question about national policy may require comprehensive surveillance data collected over multiple years. ### Step 2: Assess Data Completeness and Representativeness Genomic surveillance data is only useful for policy if it represents the population of interest. The data must be assessed for completeness and representativeness before it can be translated into policy recommendations. Completeness refers to whether the data covers the relevant time period, geographic area, and population. Representativeness refers to whether the data reflects the true distribution of resistance in the population. The assessment of data quality includes an evaluation of the sampling strategy. If the data comes from a convenience sample of clinical isolates, the data may not represent the broader population. If the data comes from a targeted surveillance program, the data may be biased toward specific settings or patient populations. The policy translation process must acknowledge these limitations and adjust the recommendations accordingly. ### Step 3: Connect Genomic Data to Phenotypic Outcomes The connection between genomic data and phenotypic outcomes is the critical step in the translation process. The presence of a resistance gene does not always mean that the bacterium is resistant to the antibiotic. The gene may be present but not expressed, or the gene may be present but the resistance mechanism may not affect the clinical susceptibility of the bacterium. The translation process must therefore include a comparison of genomic predictions with phenotypic susceptibility testing results. The comparison should be documented and the discrepancies should be investigated. A discrepancy between the genomic prediction and the phenotypic result may indicate a problem with the genomic analysis, a problem with the phenotypic testing, or a biological phenomenon that requires further investigation. The documentation of these discrepancies is essential for building confidence in the genomic data and for identifying areas where the genomic approach needs refinement. ### Step 4: Place the Data in Epidemiological Context Genomic data becomes policy-relevant when it is placed in the epidemiological context of the population and the setting. The data must be interpreted in the context of the local epidemiology, the national surveillance data, and the global situation. The WHO antimicrobial resistance surveillance framework provides the context for interpreting local data in the global picture. The epidemiological context includes information about the transmission dynamics of the resistant bacteria, the risk factors for infection, and the impact of the resistance on clinical outcomes. The context also includes information about the current stewardship practices and the available treatment options. The policy recommendation must be based on the full context, beyond the genomic data. ### Step 5: Develop the Policy Recommendation The policy recommendation is the final output of the translation process. The recommendation should be specific, actionable, and based on the evidence. The recommendation should also be communicated in a format that is accessible to the intended audience, which may include clinicians, public health officials, or policymakers. The recommendation should include the following elements: the specific action to be taken, the rationale for the action, the evidence supporting the action, and the expected outcome of the action. The recommendation should also include the limitations of the evidence and the conditions under which the recommendation should be revisited. ## At a Glance | Translation Step | Primary Question | Key Data Input | Policy Output | Common Limitation | | --- | --- | --- | --- | --- | | Define the policy question | What decision will the data inform? | Policy context and stakeholder input | A focused question with clear scope | The question is too broad or undefined | | Assess data quality | Does the data represent the population? | Sampling design and quality metrics | A data quality statement | The data is biased or incomplete | | Connect genotype to phenotype | Does the gene predict the outcome? | Genomic and phenotypic susceptibility data | A validated resistance prediction | The genotype and phenotype disagree | | Place in epidemiological context | What is the transmission and impact? | Surveillance data and clinical outcomes | A contextual risk assessment | The context is missing or outdated | | Develop the recommendation | What action should be taken? | All prior data and stakeholder input | An actionable policy recommendation | The recommendation is not specific | ## Data Visualization for Policy Audiences ### Visual Design Principles Data visualization is a critical tool for translating genomic data into policy-relevant information. The visualization must be designed for the target audience, which may not have a background in genomics or bioinformatics. The visualization should be simple, clear, and focused on the key message that the data is intended to communicate. The design principles for policy-oriented visualizations include the following: the visualization should have a clear title that states the message, the axes should be labeled with plain-language terms, the colors should be accessible to color-blind viewers, and the visualization should include a brief interpretation of the data. The visualization should not include unnecessary detail that distracts from the main message. ### Visualization Types for Genomic Data Several visualization types are useful for communicating genomic data to policy audiences. A phylogenetic tree can show the relatedness of bacterial isolates and the spread of a resistant clone. A heat map can show the distribution of resistance genes across different isolates or settings. A bar chart can show the prevalence of resistance genes in different populations. A map can show the geographic distribution of resistant bacteria. The choice of visualization type depends on the policy question and the data available. A phylogenetic tree is useful for understanding transmission dynamics, while a heat map is useful for comparing resistance profiles across settings. The visualization should be selected based on the message that the policy needs to convey. ### Visualization Pitfalls The visualization of genomic data has several pitfalls that can mislead policy audiences. The visualization may overstate the significance of the data, the visualization may be too complex for the audience, or the visualization may be misinterpreted. The visualization should be tested with the target audience before it is used in a policy document. The visualization should also be accompanied by a clear interpretation that explains what the data shows and what it does not show. The interpretation should acknowledge the limitations of the data and the uncertainty in the findings. The visualization should not be used to make claims that the data does not support. ## Risk Assessment and Prioritization ### The Risk Assessment Framework Risk assessment is the process of evaluating the likelihood and impact of a threat. In the context of genomic AMR data, the risk assessment evaluates the likelihood that a resistant bacterium will spread and the impact of that spread on public health. The risk assessment is used to prioritize the policy actions and to allocate resources. The risk assessment framework includes the following components: the hazard, the exposure, the vulnerability, and the impact. The hazard is the resistant bacterium or the resistance gene. The exposure is the population that is exposed to the hazard. The vulnerability is the susceptibility of the population to the hazard. The impact is the health and economic consequences of the hazard. ### Risk Prioritization The risk assessment is used to prioritize the policy actions. The actions are prioritized based on the likelihood and impact of the risk. The high-risk actions are prioritized over the low-risk actions. The prioritization is used to allocate resources to the most important actions. The prioritization should be based on the evidence and should be transparent. The prioritization should be reviewed and updated as new data becomes available. The prioritization should also be communicated to the stakeholders. ### Risk Communication The risk assessment is communicated to the stakeholders through a risk communication plan. The risk communication plan should be designed to the target audience and should be clear and transparent. The risk communication should acknowledge the uncertainty in the risk assessment and the limitations of the data. The risk communication should also include the recommended actions and the rationale for the actions. The risk communication should be used to build trust and to support the policy decisions. ## Stakeholder Communication and Engagement ### Identifying the Stakeholders The translation of genomic data to policy requires the engagement of a range of stakeholders. The stakeholders include the clinicians, the public health officials, the policymakers, the laboratory professionals, and the community. The stakeholders have different needs and different levels of understanding of the genomic data. The stakeholder engagement should be planned and should include the identification of the stakeholders, the assessment of their needs, and the development of a communication plan. The communication plan should be tailored to the needs of each stakeholder group. ### Communication Strategies The communication strategies for genomic data should be tailored to the audience. The clinicians may need information about the clinical implications of the data. The public health officials may need information about the surveillance and the control measures. The policymakers may need information about the policy options and the resource implications. The communication should be clear, concise, and focused on the message. The communication should also be transparent about the limitations of the data and the uncertainty in the analysis. The communication should be used to build trust and support the policy decisions. ### Building Trust and Credibility The translation of genomic data to policy requires the trust and credibility of the stakeholders. The trust is built through the transparency of the data and the analysis, the accuracy of the recommendations, and the consistency of the communication. The credibility is built through the use of the established standards and the quality of the data. The trust and credibility are maintained through the ongoing engagement with the stakeholders and the continuous improvement of the translation process. The trust and credibility are also maintained through the acknowledgment of the limitations and the uncertainty in the data. ## Common Failure Patterns in Genomic Data Translation ### Overinterpretation of Genomic Data A common failure pattern is the overinterpretation of genomic data. The presence of a resistance gene is interpreted as the presence of resistance, without the confirmation of the phenotypic expression. The overinterpretation can lead to the unnecessary use of the antibiotics or the unnecessary implementation of the control measures. The overinterpretation is avoided by the validation of the genomic data with the phenotypic data and the acknowledgment of the limitations of the genomic data. The overinterpretation is also avoided by the use of the established standards for the interpretation of the genomic data. ### Data Silos and Fragmentation Another common failure pattern is the fragmentation of the data. The genomic data may be collected by different laboratories, using different methods, and stored in different databases. The fragmentation of the data makes it difficult to compare the data across the settings and to identify the trends. The fragmentation is addressed by the standardization of the data collection and the analysis methods. The fragmentation is also addressed by the sharing of the data and the collaboration between the laboratories and the public health agencies. ### Communication Gaps A third common failure pattern is the communication gap between the laboratory and the policy. The laboratory may produce the genomic data without the context or the interpretation that the policy needs. The policy may not understand the genomic data or the implications of the data. The communication gap is addressed by the development of the communication plan and the engagement of the stakeholders. The communication gap is addressed by the translation of the genomic data into the plain-language recommendations. ### Lack of Phenotypic Confirmation A fourth common failure pattern is the lack of the phenotypic confirmation of the genomic data. The genomic data may be used to make the policy decisions without the confirmation of the phenotypic testing. The lack of the confirmation can lead to the false predictions and the inappropriate actions. The lack of the confirmation is addressed by the validation of the genomic data against the phenotypic testing. The lack of the confirmation is addressed by the use of the established standards for the antimicrobial susceptibility testing. ## Records and Measurements ### Documentation Requirements The translation of genomic data to policy requires the documentation of the data and the analysis. The documentation should include the following: the source of the data, the methods used to collect the data, the methods used to analyze the data, the results of the analysis, and the limitations of the data. The documentation should be complete and accurate. The documentation should be stored in a secure and accessible location. The documentation should be available for the review and the audit. ### Data Management The data management is the process of the collection, the storage, the analysis, and the sharing of the data. The data management should be planned and implemented. The data management should include the following: the data collection, the data storage, the data analysis, and the data sharing. The data management should be consistent with the established standards and the regulations. The data management should be documented and the data should be available for the review and the audit. ### Quality Control Records The quality control records are the documentation of the quality control activities. The quality control records should include the following: the quality control results, the quality control procedures, and the quality control actions. The quality control records should be complete and accurate. The quality control records should be stored in a secure and accessible location. The quality control records should be available for the review and the audit. ## Biosafety and Laboratory Practice ### Biosafety Principles The genomic surveillance work involves the handling of the bacterial cultures and the genomic material. The biosafety principles are the foundation of the laboratory practice. The biosafety principles include the following: the risk assessment, the containment, the decontamination, and the personal protective equipment. The biosafety principles are described in the Biosafety in Microbiological and Biomedical Laboratories manual from the CDC and NIH. The manual provides the guidance for the safe handling of the biological materials and the containment of the biological hazards. ### Laboratory Practice The laboratory practice for the genomic surveillance should follow the established standards and the guidelines. The laboratory practice should include the following: the use of the authenticated materials, the quality control of the methods, and the documentation of the results. The laboratory practice should be consistent with the professional standards of the microbiology. The American Society for Microbiology provides the professional education and the laboratory practice context for the microbiology professionals. ### The Role of the Laboratory Professional The laboratory professional plays a critical role in the translation of the genomic data to the policy. The laboratory professional is responsible for the quality of the data, the interpretation of the data, and the communication of the data. The laboratory professional should have the training and the experience in the genomic data analysis and the antimicrobial resistance. The laboratory professional should also have the knowledge of the policy and the public health context. The laboratory professional should be able to communicate the data to the policy audiences and to support the policy decisions. ## The Role of Official Methods and Standards ### Official Methods for Food Microbiology The official methods for the food microbiology are the basis for the food safety and the public health. The Bacteriological Analytical Manual of the U.S. Food and Drug Administration provides the official methods for the food microbiology. The methods are used for the detection and the identification of the foodborne bacteria. The genomic data can be used to the official methods for the food microbiology. The genomic data can be used to the identification of the bacteria and the characterization of the resistance. The genomic data can be used to the surveillance of the foodborne bacteria. ### The Standards for the Antimicrobial Susceptibility Testing The standards for the antimicrobial susceptibility testing are the basis for the interpretation of the resistance data. The Clinical and Laboratory Standards Institute provides the standards for the antimicrobial susceptibility testing. The standards are used for the interpretation of the phenotypic data and the validation of the genomic data. The standards are the basis for the clinical decisions and the public health decisions. The standards are used for the surveillance and the stewardship. The standards are the basis for the translation of the genomic data to the policy. ## The Global Context of Antimicrobial Resistance ### The Global Threat Antimicrobial resistance is a global public health threat. The World Health Organization identifies antimicrobial resistance as a global health concern that requires the coordinated action. The WHO provides the global context for the antimicrobial resistance surveillance and the stewardship. The genomic data is a tool for the global surveillance of the antimicrobial resistance. The genomic data can be used to the global distribution of the resistance and the emergence of the new resistance mechanisms. The genomic data can be used to the global response to the antimicrobial resistance. ### The Global Surveillance The global surveillance of the antimicrobial resistance is the basis for the global policy. The global surveillance is the collection and the analysis of the data from the different countries and the settings. The global surveillance is the basis for the global policy and the global action. The genomic data is a component of the global surveillance. The genomic data is used to the global distribution of the resistance and the emergence of the new resistance mechanisms. The genomic data is used to the global policy and the global action. ### The Global Policy The global policy for the antimicrobial resistance is the basis for the global action. The global policy is the framework for the surveillance, the stewardship, and the prevention. The global policy is the basis for the national policy and the local policy. The genomic data is used to the global policy. The genomic data is used to the global distribution of the resistance and the emergence of the new resistance mechanisms. The genomic data is used to the global policy and the global action. ## The Implementation of the Policy ### The Implementation Plan The implementation of the policy is the process of the policy into the action. The implementation plan should include the following: the specific actions, the timeline, the resources, and the responsibilities. The implementation plan should be developed and the implementation should be monitored. The implementation plan should be based on the evidence and the context. The implementation plan should be communicated to the stakeholders and the implementation should be evaluated. ### The Monitoring and the Evaluation The monitoring and the evaluation of the policy is the process of the assessment of the policy. The monitoring and the evaluation should include the following: the indicators, the data, and the evaluation. The monitoring and the evaluation should be used to the policy and the implementation. The monitoring and the evaluation should be the evidence and the context. The monitoring and the evaluation should be communicated to the stakeholders and the evaluation should be used to the policy. ### The Escalation Criteria The escalation criteria are the criteria for the escalation of the policy. The escalation criteria should be defined and the escalation should be documented. The escalation criteria should be the basis for the escalation of the policy. The escalation criteria should include the following: the severity of the risk, the impact of the risk, and the response. The escalation criteria should be used to the escalation of the policy and the allocation of the resources. ## The Limitations of the Genomic Data ### The Limitations of the Genomic Data The genomic data has the limitations that should be acknowledged. The genomic data is the data of the genetic material, not the data of the phenotype. The genomic data is the data of the presence of the genes, not the data of the expression of the genes. The genomic data is the data of the sample, not the data of the population. The genomic data is the data of the time, not the data of the time. The genomic data is the data of the location, not the data of the location. ### The Limitations of the Analysis The analysis of the genomic data has the limitations. The analysis is the analysis of the data, not the analysis of the biology. The analysis is the analysis of the data, not the analysis of the context. The analysis is the analysis of the data, not the analysis of the policy. The analysis is the analysis of the data, not the analysis of the decision. The analysis is the analysis of the data, not the analysis of the action. ### The Limitations of the Policy The policy has the limitations. The policy is the policy of the data, not the policy of the context. The policy is the policy of the data, not the policy of the action. The policy is the policy of the data, not the policy of the outcome. The policy is the policy of the data, not the policy of the impact. The policy is the policy of the data, not the policy of the result. ## The Future of the Genomic Data Policy ### The Future of the Genomic Data The future of the genomic data is the future of the data. The future of the genomic data is the future of the analysis. The future of the genomic data is the future of the policy. The future of the genomic data is the future of the surveillance. The future of the genomic data is the future of the stewardship. The future of the genomic data is the future of the prevention. ### The Future of the Policy The future of the policy is the future of the action. The future of the policy is the future of the implementation. The future of the policy is the future of the evaluation. The future of the policy is the future of the global action. The future of the policy is the future of the global surveillance. The future of the policy is the future of the global stewardship. ### The Future of the Translation The future of the translation is the future of the communication. The future of the translation is the future of the engagement. The future of the translation is the future of the trust. The future of the translation is the future of the data. The future of the translation is the future of the analysis. The future of the translation is the future of the policy. ## Decision Matrix for Genomic AMR Policy Actions ### The Need for a Structured Decision Tool Policymakers often receive genomic surveillance outputs without a transparent method for converting those outputs into specific actions. The absence of a structured decision tool leads to inconsistent responses, delayed interventions, or overreaction to findings that do not warrant immediate policy change. A decision matrix provides a repeatable method for evaluating genomic evidence against defined criteria and selecting from a pre-approved set of policy responses. The matrix approach works because it forces explicit consideration of the factors that matter most for policy: the strength of the genomic evidence, the phenotypic confirmation status, the epidemiological context, and the potential impact of inaction. Each factor is scored against defined thresholds, and the combined score directs the user to a specific action category. This structure reduces the influence of individual interpretation and makes the reasoning behind each policy decision transparent and auditable. ### Matrix Design and Scoring The decision matrix uses four scoring domains, each rated on a three-point scale. The first domain is evidence strength, which assesses the quality of the genomic data. A score of one indicates preliminary data from a single isolate with limited quality metrics. A score of two indicates data from multiple isolates with consistent quality metrics and authenticated reference controls. A score of three indicates data from a validated surveillance program with documented quality assurance and authenticated reference materials from a culture collection such as the American Type Culture Collection. The second domain is phenotypic confirmation. A score of one means no phenotypic susceptibility testing has been performed. A score of two means phenotypic testing is underway but results are not final. A score of three means phenotypic testing has been completed using standards-based methods from the Clinical and Laboratory Standards Institute and the results confirm the genomic prediction. The third domain is epidemiological impact. A score of one means the finding is limited to a single isolate with no evidence of transmission. A score of two means the finding involves multiple isolates in a single setting or a localized cluster. A score of three means the finding indicates spread across settings, geographic regions, or a novel resistance mechanism with potential for widespread dissemination. The fourth domain is intervention urgency. A score of one means the finding does not require immediate action and can be addressed through routine surveillance. A score of two means the finding warrants enhanced surveillance or targeted stewardship within a defined time frame. A score of three means the finding requires immediate action to prevent transmission or clinical harm. ### Matrix Scoring and Response Categories The total score ranges from four to twelve. A total score of four to six places the finding in the monitoring category. The policy response is to continue routine surveillance, document the finding in the surveillance database, and review the finding at the next scheduled surveillance review. No immediate intervention is required. A total score of seven to nine places the finding in the enhanced surveillance category. The policy response is to increase sampling frequency, expand the geographic or population scope of surveillance, and issue a communication to relevant clinical and public health stakeholders. The finding should be reviewed within a defined time frame, typically within 30 days. A total score of ten to twelve places the finding in the immediate action category. The policy response is to implement infection control measures, issue a public health advisory, and escalate the finding to the appropriate public health authority. The response should include a timeline for review and a plan for evaluating the effectiveness of the intervention. ### Practical Implementation Steps The matrix should be applied by a designated review team that includes a laboratory professional, a public health official, and a clinical representative. The team should meet on a defined schedule, such as weekly or monthly, to review new genomic findings. Each finding should be scored independently by at least two team members, and the scores should be compared. Discrepancies in scoring should be discussed and resolved through consensus. The scoring process should be documented in a standard form that includes the isolate identifier, the genomic finding, the phenotypic result, the epidemiological context, and the scores for each domain. The form should also include the final response category and the assigned actions. The completed forms should be stored with the surveillance records and made available for audit. ### Records and Measurements The matrix requires a record system that tracks the score, the response category, and the outcome of the action. The record should include the date of the review, the team members present, the scores assigned, and the final decision. The record should also include the date of the follow-up review and the outcome of the intervention. The records should be reviewed quarterly to assess the performance of the matrix. The review should examine the distribution of scores, the number of findings in each response category, and the outcomes of the actions taken. The review should also identify any findings that were scored incorrectly or any actions that did not produce the expected outcome. The findings of the review should be used to refine the matrix and the implementation process. ### Common Failure Patterns A common failure pattern is the use of the matrix without the phenotypic confirmation. The matrix is designed to require phenotypic confirmation for the higher response categories, but the team may be tempted to assign a high score based on the genomic data alone. This failure is avoided by enforcing the requirement that a score of three in the phenotypic confirmation domain requires completed standards-based testing. Another failure pattern is the inconsistent scoring of the epidemiological impact domain. The team may disagree on whether a finding represents a localized cluster or a broader transmission event. This failure is avoided by defining the terms in the matrix and by using the surveillance data to support the scoring. The team should also document the rationale for the score in the review form. A third failure pattern is the delay in the review of the findings. The matrix is only effective if the findings are reviewed on the defined schedule. The delay in the review can allow the resistant bacteria to spread before the action is taken. The delay is avoided by assigning a responsible person for the review schedule and by monitoring the timeliness of the reviews. ### Escalation Criteria The matrix includes the escalation criteria for the findings that require the immediate action. The escalation is appropriate when the total score is ten or higher, when the finding indicates a novel resistance mechanism, or when the finding indicates a potential outbreak. The escalation should include the genomic data, the phenotypic confirmation, and the epidemiological context. The escalation should be documented and the escalation should be communicated to the relevant public health authority. The escalation should also be considered when the matrix score is in the enhanced surveillance category but the epidemiological context suggests a higher risk. The team should document the rationale for the escalation and the action taken. The escalation should be reviewed at the next surveillance review to determine whether the action was appropriate and whether the finding should be reclassified. ### Biosafety and Laboratory Practice Context The matrix is a decision tool that operates alongside the laboratory practice. The laboratory professional is responsible for the quality of the genomic data and the phenotypic confirmation. The laboratory practice should follow the biosafety principles described in the Biosafety in Microbiological and Biomedical Laboratories manual from the CDC and NIH. The laboratory professional should also follow the professional standards of the microbiology, as described by the American Society for Microbiology. The matrix does not replace the laboratory quality control or the biosafety practices. The matrix is used after the data has been generated and the quality has been assessed. The matrix is used to interpret the data and to select the policy response. The laboratory professional should be a member of the review team and should provide the interpretation of the genomic data and the phenotypic results. ### Limitations of the Matrix The matrix is a decision support tool, not a substitute for the professional judgment. The matrix provides a structured approach, but the team should use the judgment to interpret the findings and to select the action. The matrix is also limited by the quality of the data. The matrix cannot compensate for the poor quality of the genomic data or the lack of the phenotypic confirmation. The matrix is also limited by the context. The matrix does not include the local context, the clinical context, or the resource context. The team should consider the context when applying the matrix and when selecting the action. The matrix should be reviewed and updated as the new data becomes available and as the policy context changes. ## Frequently Asked Questions ### What is the first step in translating genomic AMR data into policy? The first step is to define the specific policy question that the data will address. This includes the population of interest, the time frame, the geographic scope, and the decision point. A well-defined question determines the type of data needed and the analysis methods required. ### How do I validate genomic resistance predictions? Genomic resistance predictions should be validated against phenotypic antimicrobial susceptibility testing using established standards. The Clinical and Laboratory Standards Institute provides standards-based approaches for susceptibility testing that serve as the interpretive framework for genomic data. ### What are the common failure patterns in genomic data translation? Common failure patterns include over-interpreting genomic data without phenotypic confirmation, data fragmentation across laboratories and databases, communication gaps between laboratory and policy teams, and the lack of phenotypic validation for genomic predictions. ### How should genomic data be visualized for policy audiences? Visualizations should be simple, clear, and focused on the policy message. Common types include phylogenetic plots for transmission dynamics, heat maps for resistance gene distribution, and bar charts for prevalence comparisons. Each visualization should include a plain-language interpretation. ### What is the role of culture collections in genomic surveillance? Authenticated culture collections provide reference materials for validating sequencing and bioinformatic pipelines. The American Type Culture Collection provides authenticated biological materials that serve as quality control for genomic surveillance work. ### How does the WHO frame antimicrobial resistance surveillance? The World Health Organization identifies antimicrobial resistance as a global public health concern requiring coordinated surveillance and stewardship across human health, animal health, and environmental sectors. Genomic data contributes to this coordinated surveillance framework. ### What are the limitations of genomic data for policy decisions? Genomic data indicates the presence of resistance genes but does not confirm gene expression or clinical resistance. The data represents the sample, not the population, and requires phenotypic confirmation and epidemiological context for policy decisions. ### When should a laboratory escalate genomic findings to public health officials? Escalation is appropriate when genomic data indicates a novel resistance mechanism, a potential outbreak, or a significant change in resistance patterns. The escalation should include the genomic data, the phenotypic confirmation, and the epidemiological context. ## Using the Evidence | Source | Best use in this topic | Important limitation | |---|---|---| | [Biosafety in Microbiological and Biomedical Laboratories](https://www.cdc.gov/labs/bmbl/index.html) | official guidance | Check the linked page for current local requirements | | [Microbiology Resources](https://asm.org/) | official guidance | Check the linked page for current local requirements | | [Antimicrobial Resistance](https://www.who.int/health-topics/antimicrobial-resistance) | official guidance | Check the linked page for current local requirements | ## Related Bacteriology Guides - [Salmonellosis in Poultry: Public Health and Flock Management](/knowledge/bacteria/avian-bacteria/salmonellosis-in-poultry) - [Bacterial Carriage in Ducks: Pathogens of Public Health Concern](/knowledge/bacteria/avian-bacteria/bacteria-carried-by-ducks) - [Campylobacteriosis in Chickens: Food Safety and Public Health Implications](/knowledge/bacteria/avian-bacteria/campylobacteriosis-chickens-food-safety-public-health) - [Salmonella in Poultry: Food Safety and Public Health Concerns](/knowledge/bacteria/avian-bacteria/salmonella-poultry-food-safety) - [Salmonella in Poultry: Pathogenesis, Epidemiology, and Public Health Implications](/knowledge/bacteria/avian-bacteria/salmonella-poultry-pathogenesis-epidemiology) ## References and Further Reading - [Biosafety in Microbiological and Biomedical Laboratories](https://www.cdc.gov/labs/bmbl/index.html). CDC and NIH. - [Microbiology Resources](https://asm.org/). American Society for Microbiology. - [Antimicrobial Resistance](https://www.who.int/health-topics/antimicrobial-resistance). World Health Organization. - [Bacteriological Analytical Manual](https://www.fda.gov/food/laboratory-methods-food/bacteriological-analytical-manual-bam). U.S. Food and Drug Administration. - [Antimicrobial Susceptibility Testing](https://clsi.org/standards/products/microbiology). Clinical and Laboratory Standards Institute. - [Culture Collections](https://www.atcc.org/). American Type Culture Collection. - [NCBI Pathogen Detection](https://www.ncbi.nlm.nih.gov/pathogens). National Center for Biotechnology Information. - [Global, regional, and national burden of tuberculosis and multidrug-resistant tuberculosis by HIV status, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023.](https://pubmed.ncbi.nlm.nih.gov/42385762). The Lancet. Infectious diseases, 2026. - [Burden of 375 diseases and injuries, risk-attributable burden of 88 risk factors, and healthy life expectancy in 204 countries and territories, including 660 subnational locations, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023.](https://pubmed.ncbi.nlm.nih.gov/41092926). Lancet (London, England), 2025. - [Association between Mental Disorders and Subsequent Medical Conditions.](https://pubmed.ncbi.nlm.nih.gov/32348643). The New England journal of medicine, 2020. - [Global burden of enteric infectious diseases, diarrhoeal diseases, and corresponding aetiologies, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023.](https://pubmed.ncbi.nlm.nih.gov/42229499). The Lancet. Infectious diseases, 2026. > This article is educational and does not replace validated laboratory procedures, clinical diagnosis, institutional biosafety review, or public-health guidance.